Fresenius SE KGaA (XTRA:FRE) - Aktienkurs, Nachrichten und Analyse

Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

FRE Aktienübersicht

Die Fresenius SE & Co. KGaA, ein Gesundheitskonzern, bietet Produkte und Dienstleistungen für chronisch kranke Patienten an.

Über das Unternehmen

FRE fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	3/6
Past Performance	1/6
Financial Health	3/6
Dividends	0/6

Belohnungen

61.2% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 24.42% pro Jahr

Analysten sind sich einig, dass der Aktienkurs um 26.9%

Risikoanalyse

Zinszahlungen sind nicht ausreichend durch Erträge gedeckt

Die Gewinnspannen (1.4%) sind niedriger als im Vorjahr (6.1%)

Fresenius SE & Co. KGaA Wettbewerber

Fresenius Medical Care

XTRA:FME

€11.7b

SYNLAB

XTRA:SYAB

€2.4b

Carl Zeiss Meditec

XTRA:AFX

€7.6b

Labcorp Holdings

NYSE:LH

US$16.6b

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for Fresenius SE KGaA
Historical stock prices
Current Share Price	€30.30
52 Week High	€31.22
52 Week Low	€23.93
Beta	1.04
1 Month Change	5.69%
3 Month Change	18.82%
1 Year Change	19.10%
3 Year Change	-32.91%
5 Year Change	-34.79%
Change since IPO	2,583.81%

Aktuelle Nachrichten und Updates

At €29.20, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

May 28

With Fresenius SE & Co. KGaA (ETR:FRE) It Looks Like You'll Get What You Pay For

May 02

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Mar 29

Recent updates

At €29.20, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

May 28

With Fresenius SE & Co. KGaA (ETR:FRE) It Looks Like You'll Get What You Pay For

May 02

Fresenius SE & Co. KGaA (ETR:FRE) Analysts Just Trimmed Their Revenue Forecasts By 34%

Nov 10

Fresenius SE KGaA (ETR:FRE) Is Reinvesting At Lower Rates Of Return

Oct 27

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Sep 03

Some Investors May Be Worried About Fresenius SE KGaA's (ETR:FRE) Returns On Capital

Jul 25

We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

Jun 19

At €25.59, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Jun 01

Capital Allocation Trends At Fresenius SE KGaA (ETR:FRE) Aren't Ideal

Apr 18

Fresenius SE KGaA's (ETR:FRE) Soft Earnings Are Actually Better Than They Appear

Mar 13

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Mar 10

Are Investors Undervaluing Fresenius SE & Co. KGaA (ETR:FRE) By 38%?

Feb 23

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Feb 08

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Jan 03

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Nov 28

Should You Investigate Fresenius SE & Co. KGaA (ETR:FRE) At €21.71?

Oct 23

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Oct 01

Is Fresenius SE KGaA (ETR:FRE) Using Too Much Debt?

Aug 07

Is It Time To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Jul 20

Fresenius SE KGaA (ETR:FRE) May Have Issues Allocating Its Capital

Jul 02

Fresenius SE KGaA (ETR:FRE) Is Increasing Its Dividend To €0.92

Apr 28

At €34.09, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Apr 17

Fresenius SE KGaA (ETR:FRE) Is Paying Out A Larger Dividend Than Last Year

Apr 02

Fresenius SE KGaA (ETR:FRE) Could Be Struggling To Allocate Capital

Mar 27

Fresenius SE KGaA's (ETR:FRE) Upcoming Dividend Will Be Larger Than Last Year's

Feb 24

Is Now An Opportune Moment To Examine Fresenius SE & Co. KGaA (ETR:FRE)?

Jan 13

Here's Why Fresenius SE KGaA (ETR:FRE) Has A Meaningful Debt Burden

Dec 29

Fresenius SE KGaA (ETR:FRE) Could Be Struggling To Allocate Capital

Dec 14

At €41.20, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Oct 15

Is Fresenius SE KGaA (ETR:FRE) A Risky Investment?

Sep 30

Fresenius SE KGaA (ETR:FRE) Is Reinvesting At Lower Rates Of Return

Sep 15

Is Now The Time To Look At Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Jul 17

Fresenius SE KGaA (ETR:FRE) Takes On Some Risk With Its Use Of Debt

Jul 01

Aktionärsrenditen

	FRE	DE Healthcare	DE Markt
7D	3.9%	2.5%	-0.2%
1Y	19.1%	8.2%	3.5%

Rendite im Vergleich zur Industrie: FRE übertraf die Branche German Healthcare, die im vergangenen Jahr eine Rendite von 3.9 erzielte.

Rendite vs. Markt: FRE übertraf den Markt German, der im vergangenen Jahr eine Rendite von 9.1 erzielte.

Preisvolatilität

Is FRE's price volatile compared to industry and market?
FRE volatility
FRE Average Weekly Movement	2.7%
Healthcare Industry Average Movement	5.7%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.2%
10% least volatile stocks in DE Market	2.5%

Stabiler Aktienkurs: FRE hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.

Volatilität im Zeitverlauf: FREDie wöchentliche Volatilität (3%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1912	190,863	Michael Sen	www.fresenius.com

Die Fresenius SE & Co. KGaA ist ein Gesundheitskonzern, der Produkte und Dienstleistungen für chronisch kranke Menschen anbietet. Das Unternehmen ist in vier Segmenten tätig: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios und Fresenius Vamed. Das Segment Fresenius Medical Care bietet Produkte und Dienstleistungen für Patienten mit chronischem Nierenversagen an.

Fresenius SE & Co. KGaA's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Fresenius SE KGaA im Vergleich zum Marktanteil des Unternehmens?
FRE grundlegende Statistiken
Marktanteil	€17.07b
Gewinn(TTM)	€312.00m
Umsatz(TTM)	€22.46b

54.7x

Kurs-Gewinn-Verhältnis

0.8x

Kurs-Umsatz-Verhältnis

Ist FRE zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
FRE Gewinn- und Verlustrechnung (TTM)
Einnahmen	€22.46b
Kosten der Einnahmen	€17.35b
Bruttogewinn	€5.11b
Sonstige Ausgaben	€4.79b
Umsatz	€312.00m

Zuletzt gemeldete Gewinne

Mar 31, 2024

Datum des nächsten Gewinnberichts

Jul 31, 2024

Gewinn per Aktie (EPS)	0.55
Bruttomarge	22.74%
Nettogewinnspanne	1.39%
Schulden/Eigenkapital-Verhältnis	62.2%

Wie hat sich FRE auf lange Sicht entwickelt?

Historische Performance und Vergleiche

FRE Aktienübersicht

Belohnungen

Risikoanalyse

Fresenius SE & Co. KGaA Wettbewerber

XTRA:FME

€11.7b

XTRA:SYAB

€2.4b

XTRA:AFX

€7.6b

NYSE:LH

US$16.6b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

At €29.20, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

First quarter 2024 earnings released: EPS: €0.49 (vs €0.61 in 1Q 2023)

PAI Mid-Market Fund SCSp. managed by PAI Partners agreed to acquire 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

With Fresenius SE & Co. KGaA (ETR:FRE) It Looks Like You'll Get What You Pay For

Verme family with other shareholders completed the acquisition of additional 70% stake in Clinica Ricardo Palma S.A. from Fresenius SE & Co. KGaA (XTRA:FRE).

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Recent updates

At €29.20, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

First quarter 2024 earnings released: EPS: €0.49 (vs €0.61 in 1Q 2023)

PAI Mid-Market Fund SCSp. managed by PAI Partners agreed to acquire 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

With Fresenius SE & Co. KGaA (ETR:FRE) It Looks Like You'll Get What You Pay For

Verme family with other shareholders completed the acquisition of additional 70% stake in Clinica Ricardo Palma S.A. from Fresenius SE & Co. KGaA (XTRA:FRE).

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

New major risk - Financial position

Fresenius SE KGaA (ETR:FRE) Could Be At Risk Of Shrinking As A Company

Consensus EPS estimates fall by 11%

Why Fresenius SE & Co. KGaA (ETR:FRE) Could Be Worth Watching

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC completed the acquisition of EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE).

Consensus EPS estimates fall by 15%

Consensus EPS estimates fall by 15%

German Fresenius Reportedly Seeks to Sell Vamed Reha

Consensus EPS estimates fall by 20%

Consensus EPS estimates fall by 20%

A Look At The Fair Value Of Fresenius SE & Co. KGaA (ETR:FRE)

Fresenius SE & Co. KGaA's (ETR:FRE) Shares Not Telling The Full Story

Fresenius SE & Co. KGaA to Report Fiscal Year 2023 Final Results on Mar 14, 2024

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Consensus EPS estimates increase by 57%

Fresenius SE & Co. KGaA (ETR:FRE) Analysts Just Trimmed Their Revenue Forecasts By 34%

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC agreed to acquire EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE) for €500 million.

Third quarter 2023 earnings released: €0.72 loss per share (vs €0.57 profit in 3Q 2022)

Consensus revenue estimates decrease by 46%

Fresenius SE & Co. KGaA to Report Q2, 2024 Results on Jul 31, 2024

Fresenius SE KGaA (ETR:FRE) Is Reinvesting At Lower Rates Of Return

KKR in Talks to Buy Eugin from Fresenius

Fresenius Reportedly Plans to Offload Digital Subsidiary Curalie

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Consensus EPS estimates fall by 14%

New major risk - Financial position

Second quarter 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates increase by 14%

Fresenius SE & Co. KGaA to Report Q3, 2023 Results on Nov 02, 2023

Some Investors May Be Worried About Fresenius SE KGaA's (ETR:FRE) Returns On Capital

We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

At €25.59, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Fresenius Se & Co. Kgaa Proposes Dividend for 2022

Upcoming dividend of €0.92 per share at 3.3% yield

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Fresenius SE & Co. KGaA to Report Q1, 2023 Results on May 09, 2023

Capital Allocation Trends At Fresenius SE KGaA (ETR:FRE) Aren't Ideal

Consensus EPS estimates fall by 17%

Fresenius SE KGaA's (ETR:FRE) Soft Earnings Are Actually Better Than They Appear

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Full year 2022 earnings: EPS misses analyst expectations

Are Investors Undervaluing Fresenius SE & Co. KGaA (ETR:FRE) By 38%?

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Fresenius SE & Co. KGaA, Annual General Meeting, May 17, 2023

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

QIC Reportedly Set to Clinch Healius Day Hospital Unit for $140 Million Plus

Third quarter 2022 earnings released: EPS: €0.57 (vs €0.74 in 3Q 2021)

Should You Investigate Fresenius SE & Co. KGaA (ETR:FRE) At €21.71?

Brookfield Reportedly Drops Out of Race to Buy Healius

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Fresenius SE Announces Chief Financial Officer Changes

Fresenius SE & Co. KGaA Announces Michael Sen as CEO on October 1, 2022 Succeeding Stephan Sturm

Erträge & Einnahmen